RE:RE:RE:RE:RE:RE:RE:RE:RE:AstraZeneca's ADC disappoints - on severe adverse eventsJuly 2024 - Bristol Myers Squibb (BMS) has ended their global strategic agreement with Eisai for their antibody-drug conjugate (ADC). The Japanese pharma will now exclusively own and be responsible for the investigational antibody-drug conjugate farletuzumab ecteribulin.
As part of the termination, Eisai will also refund BMS $200 million, which represents the unused portion of the initial R&D funds it received under the original agreement. In June 2021 the agreement saw the New Jersey pharma pay $650 million upfront plus the $200 million sum meant to shoulder Eisai’s R&D expenses. Under the deal, Eisai was also eligible for up to $2.45 billion in development, regulatory and commercial milestones.
Farletuzumab ecteribulin is an investigational ADC that uses a humanized IgG1 monoclonal antibody targeting the FRα protein, which is highly expressed in several types of cancers. The ADC’s toxic payload is eribulin, an inhibitor of microtubule dynamics. When released inside cancer cells, eribulin prevents cell division and can trigger cell death.
https://www.biospace.com/article/eisai-assumes-sole-responsibility-for-adc-after-collaboration-with-bms-ends/